Analysts expect NewLink Genetics Corporation (NASDAQ:NLNK) to announce $2.72 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for NewLink Genetics Corporation’s earnings. The lowest sales estimate is $300,000.00 and the highest is $5.00 million. NewLink Genetics Corporation reported sales of $12.70 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 78.6%. The company is expected to issue its next earnings report on Tuesday, February 27th.

On average, analysts expect that NewLink Genetics Corporation will report full year sales of $2.72 million for the current financial year, with estimates ranging from $18.61 million to $23.60 million. For the next financial year, analysts expect that the business will post sales of $12.20 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover NewLink Genetics Corporation.

A number of brokerages have weighed in on NLNK. Cantor Fitzgerald reissued a “buy” rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a research report on Monday, September 25th. ValuEngine raised NewLink Genetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Zacks Investment Research raised NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research report on Saturday, July 29th. Stifel Nicolaus boosted their price target on NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Finally, Jefferies Group LLC raised NewLink Genetics Corporation from a “hold” rating to a “buy” rating and boosted their price target for the stock from $7.00 to $26.00 in a research report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.43.

In other news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of NewLink Genetics Corporation stock in a transaction dated Friday, October 6th. The stock was bought at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the completion of the acquisition, the insider now directly owns 7,857,732 shares in the company, valued at approximately $80,541,753. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 13.70% of the company’s stock.

Several large investors have recently modified their holdings of NLNK. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of NewLink Genetics Corporation by 1,823.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 9,735 shares during the period. Oppenheimer & Co. Inc. bought a new stake in shares of NewLink Genetics Corporation during the third quarter worth approximately $114,000. State of Wisconsin Investment Board bought a new stake in shares of NewLink Genetics Corporation during the second quarter worth approximately $125,000. Trexquant Investment LP boosted its stake in shares of NewLink Genetics Corporation by 39.1% in the second quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 5,097 shares during the period. Finally, Advisor Group Inc. boosted its stake in shares of NewLink Genetics Corporation by 3.4% in the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 600 shares during the period. Institutional investors own 45.31% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/2-72-million-in-sales-expected-for-newlink-genetics-corporation-nlnk-this-quarter/1702409.html.

Shares of NewLink Genetics Corporation (NASDAQ:NLNK) traded down $0.12 during midday trading on Tuesday, reaching $8.90. The company’s stock had a trading volume of 657,600 shares, compared to its average volume of 1,305,013. NewLink Genetics Corporation has a 1 year low of $5.90 and a 1 year high of $25.17.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.